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new FIL agents will increase. If the California data reflect national trends, uptake 
may continue to be slow compared with more established biosimilar markets in 
Europe.
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Expenses for anticancer treatment in France have grown substantially with an aver-
age annual cost increase of 17.7% between 1999 and 2009. This is due to access to 
expensive targeted therapies, higher cancer incidence rates and overall survival in 
patients with advanced disease.Objectives: To evaluate physician opinions and 
attitudes and their evolution between 2003 and 2013 regarding the costs of anti-
cancer treatments MethOds: Conducted in France biennially, the « Cancérologie » 
study measures physician opinions/attitudes on today’s relevant topics. Latest 
waves of this study included a series of questions on the cost of anticancer treat-
ments, allowing for analysis of the evolution of responses. In 2013 315 physicians 
who work in French public or private hospitals and prescribe antitumor treatments 
for solid and/or liquid cancer participate to the study. Results: In 2003, 54% of phy-
sicians considered cancer related budgetary issues ‘very important’. Over the years, 
this percentage progressively decreased until dropping to 25% in 2013. However, in 
2003, 68% predicted that the budgetary situation would deteriorate further com-
pared with 73% in 2013. The contrast between the pessimistic perceptions of the 
future and a reality which is perceived less and less problematic demonstrates the 
dual mindset of physicians who are at once: - Citizens conscious of how the growth 
of costs can only end in an impasse, - Clinicians whose prescriptions remain guided 
by therapeutic goals. Thus in 2013, 62% of physicians indicated that costs had little to 
no impact on their choice of treatment. cOnclusiOns: New molecule availability 
will cause costs of anticancer therapies to continue to grow at the same rate seen in 
recent years. If physicians do not take greater responsibility for their prescriptions’ 
costs, the only solution would be coercive measures.
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Objectives: In 2013, it was shown that mutations in KRAS exons 3 and 4, or NRAS 
exons 2 to 4 had a similar effect. The primary objective was to assess the practices 
in conducting RAS testing in 2014. The secondary objectives were to describe the 
evolution of the RAS testing prescription rates from 2011, the process and time 
required to obtain the results, and to analyze their impact on the therapeutic strat-
egy. MethOds: FLASH-RAS is an observational retrospective French multicenter 
study. Results: 375 mCRC patients diagnosed and initiating a 1st line treat-
ment (L1) between March and June 2014 were analyzed. For 90.1% of the patients 
(IC95%= [87.1%; 93.2%]), a genotyping request for RAS biomarkers was made in L1, 
i.e. a significantly increased rate compared to 2011 (81.1% in 2011, p< 0.001). For 75% 
of the patients, the request was made before or at least one month after the diagno-
sis of the first metastases (1st M). No increase was observed in the median and mean 
times to obtain the test results between 2011 and 2014 despite the increased number 
of exons tested. cOnclusiOns: In 2014, the rate of RAS genotyping requests has 
been increasing since 2011. For a majority of patients, the request is made before 
or at the latest one month after 1st M diagnosis. Nevertheless, for 24.5% of the 
patients, the request is made more than one month after 1st M diagnosis, which is 
not compatible with an informed treatment decision in L1.
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Objectives: The Chronic Care Model (CCM) is an accepted framework for deliv-
ering care to patients with chronic illnesses. The Patient Assessment of Chronic 
Illness Care (PACIC) is a questionnaire designed to assess the CCM from the 
patient´s perspective, focusing on the receipt of patient centered care. Our aim 
was to document patient´s assessment of chronic illness care in short-term cancer 
survivors, through PACIC MethOds: Patients with colo-rectal (CCR), breast or 
prostate cancer and who finished their treatment three years before answering 
the questionnaire were included in the study. PACIC was administered by mail 
and has 5 subscales, patient activation (PA), delivery system design (DSD), goal 
setting (GS), problem solving (PS) and follow-up coordination (FU). In addition 
there is a global score (G). Each subscale and the global are scored from 1 to 
5 with higher scores indicating patient´s perception of greater involvement in 
self- management and receipt of chronic care counseling. Data are expressed as 
mean (standard deviation). Comparison amongst location has been carried out 
through analysis of variance with Scheffé post-hoc test. PACIC has been validated 
in Spanish. Results: There were 645 patients included, 139 prostate, 339 breast 
and 167 with CCR. The mean (SD) by dimensions were: PA: 3.2 (1.4), DSD: 3.5 (1.2), 
GS: 2.6 (1.3), PS: 2.8 (1.5), FU: 2.2 (1.2) and global: 2.8 (1.2). There were statistically 
significant differences amongst cancer location in two dimensions, PS (p= 0.02) 
and FU (p = 0.002), with best scores in CCR in both cases. cOnclusiOns: To our 
knowledge this is the first time that PACIC is used in cancer patients. Patient 
activation and delivery system design have shown the best scores and follow-up, 
a critical point the worst score although with differences; being CCR survivors 
who better have evaluated this dimension
prevalence data for 6 cancers with values ranging from < 3 to > 170 per 105were 
obtained from the GLOBOCAN database. Clinicaltrials.gov was searched for phase 3 
trials for the cancers from 2005 to 2015; the NICE website was searched for technol-
ogy appraisals concerning the cancers for the same period. Results: Breast cancer 
(BC; prevalence, 174.1 per 105) had the greatest number of phase 3 clinical trials 
(n= 333) and NICE assessments (n= 10) in the period; three assessments resulted in 
recommendations. Prostate cancer (PC), having a similar prevalence to BC (162.5 per 
105), had 60% fewer phase 3 trials (n= 133) and 50% fewer NICE assessments (n= 5), 
but also resulted in three recommendations. Multiple myeloma (MM; prevalence, 
6.2 per 105) was the subject of a disproportionately high number of phase 3 trials 
(n= 98) and NICE assessments (n= 4); three assessments resulted in recommenda-
tions. In contrast, non-Hodgkin’s lymphoma, having a higher prevalence than MM 
(15.4 per 105) was the subject of only 40 phase 3 trials and 4 NICE assessments; three 
resulted in recommendations. Myelofibrosis and pancreatic cancer, each having a 
prevalence of < 5 per 105, were the subject of 11 and 25 phase 3 trials, respectively. 
One NICE assessment was performed for an intervention for myelofibrosis and had 
a negative outcome. cOnclusiOns: These results suggest that while the number 
of NICE assessments undertaken reflects the number of phase 3 trials performed 
in a given cancer, there is a mismatch between the number of assessments and the 
prevalence of specific cancers in the UK. Further research is warranted to investigate 
whether a similar mismatch is evident in other countries.
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Objectives: The Dutch minister of health made reimbursement of the first new 
melanoma drug conditional on the set-up of a population-based registry and cen-
tralisation of care. This led in 2012 to well-defined quality standards and the Dutch 
Melanoma Treatment Registry (DMTR) characterised by its unique collaboration 
between all stakeholders involved in melanoma care (public and private partner-
ship). The DMTR aims to enhance real patient value by closing the gap of the 
initial uncertainty regarding the real-world value of promising drugs in everyday 
practice. MethOds: The DMTR prospectively documents detailed data of all Dutch 
advanced melanoma patients regarding tumour- and patient characteristics, treat-
ment strategies, clinical, physical, social, emotional and well-being outcomes, 
resource use, informal care, and productivity losses. These data are used for bench-
marking and outcomes research to obtain insights into real-world cost-effective-
ness of treatment pathways to improve health decision making. Results: The 
richness of DMTR data facilitates the assessment of multiple outcomes includ-
ing quality of care, use of drugs, survival benefit, quality of life, costs and cost-
effectiveness. Physicians are fortnightly provided with feedback on their delivered 
quality of care; manufacturers are provided with information regarding the use 
and performance of their drugs. This greatly enhances learning regarding the 
use and outcomes of treatments. First results (stage IV: N= 1226; median follow-
up 12.8 months) show an improved survival (2012-2015: median OS 9.3 months 
[IQR:4.5-17.4], one-year survival rate 40%) compared to the period before the 
introduction of the new drugs (2003-2011: median OS 6.8 months [IQR:3.3-18.5], 
one-year survival rate 33%). cOnclusiOns: The DMTR provides crucial informa-
tion regarding the extent to which novel treatments offer real-world value and 
whether scarce resources are spent cost-effectively in everyday practice. Its unique 
design emphasises the essential holistic view needed in cancer management and 
can be seen as blueprint for other registries aiming at improving health decision 
making.
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Objectives: Biosimilars of filgrastim (FIL), granulocyte colony-stimulating factor 
(G-CSF), have been available in Europe since 2008. Now 2 FIL products are approved 
in the USA: tbo-filgrastim (TBO-FIL, while a biosimilar in Europe, is not techni-
cally one in the USA; approved November 2013 for a subset of FIL indications) and 
filgrastim-sndz (FIL-SNDZ, the first true US biosimilar; approved March 2015, but 
launch delayed by ongoing litigation). Our objective was to identify physician docu-
mentation and use of TBO-FIL during patient office visits. MethOds: Physician 
records were extracted (1 November 2013‒18 June 2015) from RealHealthData, a 
US medical transcription database providing data within 72 hours of each visit 
to a participating provider. Records were searched for mention of TBO-FIL: “tbo-
filgrastim,” “Granix,” or “Neutroval.” Mentions of FIL (“filgrastim” or “Neupogen”) 
and PEG (“pegfilgrastim” or “Neulasta”) were also tabulated. Results: Counts 
of mentions (and number of unique prescribers) were as follows: PEG: 1864 (40); 
FIL: 431 (53); TBO-FIL: 5 (3), with > 86% from oncologists in California. TBO-FIL 
was reported, as “Granix,” for 4 patients. Prophylactic TBO-FIL was prescribed 
for 1 chemotherapy patient and as interim treatment for 2 patients with chemo-
therapy who normally received PEG. 1 patient reported taking TBO-FIL as needed 
for neutropenia symptoms. Only 1 of the 4 received TBO-FIL as their main G-CSF 
treatment. Counts will be refreshed in October 2015 and will include FIL-SNDZ 
data, if launched and available. cOnclusiOns: Among 2300 records reporting a 
G-CSF in this snapshot of primarily Californian oncologists, only 5 mentions of 
TBO-FIL were noted in the 18 months since launch. As awareness of ‘biosimilars’ 
improves in the USA and legal barriers are overcome, it is expected that uptake of 
